Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 3/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.49 |
| ▸ | HINT1 | P49773 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12939473 | 1.00 | NT5E (0.57) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL10819909 | 1.00 | NT5E (0.57) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL12194800 | 1.00 | NT5E (0.57) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL15468735 | 1.00 | NT5E (0.57) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL18740412 | 0.96 | NT5E (0.53) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL723267 | 0.94 | NT5E (0.56) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL1576874 | 0.93 | TGM2 (0.59) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL13522449 | 0.93 | TGM2 (0.59) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL10819892 | 0.93 | TGM2 (0.59) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| Inx-09114 SCHEMBL23319265 | 0.92 | P2RY2 (0.60) | NT5EPOLBIMPDH2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130017171-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA DEGLI STUDI DI CAGLIARI (IT) | 2013-01-17 | — | — | US | claimed |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. | 2019-07-25 | — | — | US | disclosed |
| WO-2017066793-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066791-A1 | SUGAR SUBSTITUTED MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2016014527-A2 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9216960-B2 | Spiro[2.4]heptanes for treatment of Flaviviridae infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150079036-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8946242-B2 | Spiro[2.4]heptanes for treatment of flaviviridae infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8921384-B2 | Spiro[2.4]heptanes for treatment of flaviviridae infections | UNVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130217644-A1 | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2013123138-A2 | SPIRO [2.4]HEPTANES FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2476690-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2476690-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2307434-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010014134-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARAMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014134-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARAMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | NT5E 57/4885POLB 212/4885IMPDH2 186/4885 |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | NT5E 424/4885POLB 272/4885IMPDH2 320/4885 |
| US-20150079036-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | HAVCR2, SLC10A1, CYP8B1 | NT5E 4434/4885POLB 4092/4885IMPDH2 1452/4885 |
| US-20130017171-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | NT5E 407/4885POLB 842/4885IMPDH2 370/4885 |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | RNGTT, RNMT, NSUN2 | NT5E 572/4885POLB 438/4885IMPDH2 967/4885 |
| US-20130217644-A1 | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] | MTAP, NT5C3B, RNMT | NT5E 145/4885POLB 846/4885IMPDH2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.